ArticleAmerican journal of translational research2026
Photodynamic therapy with bioresorbable polymers: a novel approach to hypertrophic scar management.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the application of photodynamic therapy (PDT) combined with the bioabsorbable polymer poly (p-dioxanone) (PPDO) in the treatment of hypertrophic scars (HS).
methodsFrom April 2021 to April 2024, 120 HS patients were divided into two groups based on their treatment methods: 58 patients received PDT combined with triamcinolone acetonide (PDT+TAC group), and 62 patients received PDT combined with PPDO (PDT+PPDO group). Intergroup analyses compared clinical efficacy, Vancouver Scar Scale (VSS) scores, University of North Carolina (UNC) Scar Scale scores, pain (Visual Analogue Scale, VAS), pruritus (Four-Item Pruritus Questionnaire, FIIQ), and levels of transforming growth factor (TGF)-β1, epidermal growth factor (EGF), and bone morphogenetic protein-7 (BMP-7). Adverse reactions and short-term recurrence were recorded, as well as psychological effect (Hospital Anxiety and Depression Scale, HADS), quality of life (Dermatology Life Quality Index, DLQI), and treatment satisfaction.
resultsClinical data showed that the overall efficacy of the PDT+PPDO group was superior to that of the PDT+TAC group. At 10 months post-treatment, compared to the PDT+TAC regimen, patients receiving PDT+PPDO treatment showed significantly lower scores on the VSS, UNC, VAS, FIIQ, HADS, and DLQI scales, suppressed TGF-β1 and EGF expression, and enhanced BMP-7 expression(all P>0.05). The short-term recurrence rate was significantly lower in the PDT+PPDO group, and patients had higher satisfaction with treatment outcomes (both P>0.05).
conclusionEvidence suggests that PDT+PPDO has clinical advantages for the treatment of HS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.